Barclays Analysts Give Bayer (BAYN) a €110.00 Price Target

Barclays set a €110.00 ($127.91) price objective on Bayer (FRA:BAYN) in a research note released on Friday. The firm currently has a buy rating on the healthcare company’s stock.

Several other analysts have also issued reports on the stock. Nord/LB set a €98.00 ($113.95) price target on shares of Bayer and gave the stock a neutral rating in a research report on Monday, June 4th. Independent Research set a €95.00 ($110.47) price target on shares of Bayer and gave the stock a neutral rating in a research report on Monday, August 13th. Sanford C. Bernstein set a €120.00 ($139.53) price target on shares of Bayer and gave the stock a buy rating in a research report on Monday, July 16th. UBS Group set a €130.00 ($151.16) price target on shares of Bayer and gave the stock a buy rating in a research report on Thursday, June 7th. Finally, Warburg Research set a €120.00 ($139.53) price target on shares of Bayer and gave the stock a neutral rating in a research report on Thursday, May 3rd. Ten research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of €109.65 ($127.50).

FRA BAYN opened at €82.65 ($96.10) on Friday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: Asset Allocation and Your Retirement

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply